The risk-sharing agreement (RSA) for Strensiq Inj (asfotase alfa, AZ), a treatment for hypophosphatasia, has been successfully renewed in Korea.

The drug was last covered under the RSA scheme in June 2020, when it was listed for reimbursement in Korea under the Expenditure Cap Type and Refund Type RSA.

According to the National Health Insurance Service on the 8th, AstraZeneca and NHIS recently completed negotiations to renew the risk-sharing arrangement for 5 Strensiq Inj items. Both sides reportedly settled on appropriate terms for the agreement.

The 4-year RSA term for Strensiq Inj was set to expire on May 31, but with the renewal, the drug will continue to be reimburse